Regulating the level of septin2 sulfhydryl nitrosylation modification for pharmaceutical use

A technology of lv-septin2c111a and a drug is applied in the field of pharmaceutical use for regulating the level of sulfhydryl nitrosylation of Septin2, so as to achieve the effect of inhibiting the occurrence of aortic aneurysm and aortic dissection

Active Publication Date: 2022-02-22
NANJING MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether it can undergo sulfhydryl nitrosylation modification and its role and mechanism in cardiovascular diseases has not yet been studied or reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Regulating the level of septin2 sulfhydryl nitrosylation modification for pharmaceutical use
  • Regulating the level of septin2 sulfhydryl nitrosylation modification for pharmaceutical use
  • Regulating the level of septin2 sulfhydryl nitrosylation modification for pharmaceutical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1. Biotin-Switch method to detect sulfhydryl nitrosylation modified proteins (S-nitrosylation Protein Detection Kit from Cayman Chemical Company, Cat. No. 10006518)

[0019] (1) After the cells are treated, remove the culture medium, wash with pre-cooled wash buffer 3 times, add 500 μL wash buffer to scrape off, and transfer to a 1.5 mL centrifuge tube.

[0020] (2) Centrifuge at 500Xg at 4°C for 5 minutes, discard the supernatant.

[0021] (3) Place the cells on ice and configure Blocking buffer. Specific preparation method: Add new blocking reagent to 100 μL DMF and 900 μL buffer A to make the stock solution of blocking buffer. After mixing, add 9 mL of buffer A to obtain the blocking buffer.

[0022] (4) Add 500 μL blocking buffer to each tube to resuspend the cell pellet obtained in (2), and rotate at 4°C for 30 minutes.

[0023] (5) Centrifuge at 12,000 rpm at 4°C for 10 min, and transfer the supernatant to a 15 mL centrifuge tube.

[0024] (6) Add 4 times the vo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The pharmaceutical use of regulating the level of thiol nitrosylation modification of Septin2 belongs to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection. The present invention uses lentivirus infection into macrophages to down-regulate the mercapto nitroso at the Cys111 site of Septin2 protein Kylation modification can effectively inhibit the occurrence of aortic aneurysm and aortic dissection.

Description

technical field [0001] The invention belongs to the field of molecular biology diagnosis of aortic aneurysm and aortic dissection, and specifically relates to a pharmaceutical application for regulating the level of Septin2 thiol nitrosylation modification. Background technique [0002] Aortic aneurysm and aortic dissection (AAD) are life-threatening conditions with a high mortality rate in the event of aortic rupture. Over the past 20 years, significant advances have been made in open surgery and endovascular repair of AAD. However, drug therapies are still lacking, and therefore, the molecular and cellular mechanisms involved in the formation and development of AAD are urgently needed to be explored. The main pathological features of AAD are the loss of vascular smooth muscle cells and remodeling of the extracellular matrix due to the accumulation and activation of inflammatory cells. The inflammatory response plays a crucial role in AAD and largely influences many deter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61P9/00A61P35/00G01N27/62G01N33/574G01N33/68
CPCG01N33/6893G01N33/57407G01N33/57492G01N33/57496A61K48/0008A61K48/005A61P35/00A61P9/00G01N27/62G01N2800/329G01N2333/47
Inventor 季勇张昊张艳张旭红严科韩艺谢利平
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap